VarmX, the Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, has closed a series A financing round of € 7.5 million. The round was led by the existing shareholder BioGeneration Ventures (BGV) and regional economic development company InnovationQuarter (IQ) also invested. Uniiq also became shareholder through conversion of its start-up loan to the company. The equity financing is supplemented by the Netherlands Enterprise Agency ( with an innovation credit of € 5.0 million supplementing the financing to a total of € 12.5 million. The series A round is a follow up to the initial seed financing in June 2017 by BGV and IQ. We advised BGV and IQ.